GHNasdaqServices-Medical LaboratoriesFiscal year ends December 31

Guardant Health, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026

$157.88−0.72 (-0.45%)

Close on Oct 19, 2026

Market cap: $20.98B
P/E (TTM): –
Dividend yield: –

Guardant Health, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Revenue	982	739	564	450	374	287	214	91	50	25
Cost of Revenue	349	290	227	–	–	–	–	–	–	–
Gross Profit	633	449	337	–	–	–	–	–	–	–
Research & Development	364	348	367	374	263	150	86	51	26	11
Selling, General & Admin	706	545	451	464	399	299	140	90	69	36
Selling & Marketing	495	365	295	300	192	107	78	53	32	26
General & Administrative	211	180	156	164	207	193	61	36	37	9.92
Advertising Expenses	24	0	0	0	2.40	1.20	1.30	0.20	0.30	0.60
Total Costs & Expenses	1,419	1,183	1,129	994	785	542	297	184	126	69
Operating Income	-437	-444	-565	-544	-411	-255	-82	-93	-77	-44
Interest Expense	3.90	2.58	2.58	2.58	2.58	4.77	1.18	1.25	2.70	3.02
Interest & Investment Income	34	54	35	6.07	3.93	10	14	5.27	2.23	0.73
Other Non-Operating Income	-10	-43	53	-13	25	3.64	0.09	4.70	-1.06	0.00
Asset Impairment Charges	0	–	–	–	–	–	–	–	–	–
Gain (Loss) on Investments	0	-44	80	-7.79	–	–	–	–	–	–
Pretax Income	-418	-435	-479	-653	-384	-246	-70	-84	-83	-46
Income Tax Expense	-1.26	1.28	0.69	1.14	0.30	0.38	-1.87	0.04	0.01	0.01
Net Income incl. Noncontrolling Interests	–	-436	-479	-655	-385	-246	-68	-84	-83	-46
Net Income	-416	-436	-479	-655	-385	–	-76	-85	-83	-46
Preferred Dividends	–	–	–	–	–	–	1.10	1.10	–	–
Net Income to Common	-416	-436	-479	-655	-406	-254	-76	-85	-89	-46
EPS (Basic)(per share)	-3.32	-3.56	-4.28	-6.41	-4.00	-2.60	-0.84	-2.80	-7.07	-3.53
EPS (Diluted)(per share)	-3.32	-3.56	-4.28	-6.41	-4.00	-2.60	-0.84	-2.80	-7.07	-3.53
Shares Outstanding (Basic, Weighted)(shares)	125	123	112	102	101	98	91	30	13	13
Shares Outstanding (Diluted, Weighted)(shares)	125	123	112	102	101	98	91	30	13	13
EBITDA	-398	-401	-522	-508	-389	-239	-71	-86	-71	-40

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 65.0%
Operating margin: -39.7%
Net margin: -38.3%
Return on equity, FY2025: 348.4%

Financial strength

Current ratio: 4.03
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 310.8%

Valuation

P/E ratio: –
Price to sales: 17.73
Price to book: –
Dividend yield: –